Literature DB >> 7059438

Differential effects of enzyme induction on antipyrine metabolite formation.

M Danhof, R M Verbeek, C J van Boxtel, J K Boeijinga, D D Breimer.   

Abstract

1 The influence of enzyme induction with antipyrine and pentobarbitone was studied on the rates of formation of the major metabolites of antipyrine: 4-hydroxyantipyrine, norantipyrine and 3-hydroxymethyl-antipyrine + 3-carboxy-antipyrine. The inducing drugs were given to panels of healthy volunteers for 8 days and prior to and after this period antipyrine total elimination clearance was determined in plasma, whereas the partial clearances for production of the individual metabolites were assessed on the basis of urinary excretion data. 2 Antipyrine total clearance had significantly increased by 16% following treatment with antipyrine, which could almost entirely be attributed to a selective increase in the rate of production of norantipyrine. 3 With pentobarbitone total clearance of antipyrine had increased by 60%, which was associated with a significant increase in the clearance of production of all three metabolites. However, the increase in norantipyrine formation was significantly higher than the increase in 4-hydroxyantipyrine and 3-hydroxymethyl-antipyrine formation. 4 The most likely explanation for these differences in the degree of induction of the different metabolic routes of antipyrine, is that different enzymes are involved in the different routes. Apparently the enzyme involved in norantipyrine formation is most sensitive to induction by antipyrine and pentobarbitone. By measuring rates of antipyrine metabolite formation it may be possible to study the degree of selectivity of enzyme inducers on oxidative drug metabolism.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7059438      PMCID: PMC1402128          DOI: 10.1111/j.1365-2125.1982.tb01389.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  27 in total

1.  Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance.

Authors:  W Zilly; D D Breimer; E Richter
Journal:  Eur J Clin Pharmacol       Date:  1975-12-19       Impact factor: 2.953

2.  The effect of spironolactone on antipyrine metabolism in man.

Authors:  D H Huffman; D W Shoeman; P Pentikäinen; D L Azarnoff
Journal:  Pharmacology       Date:  1973       Impact factor: 2.547

3.  Pharmacological implications of microsomal enzyme induction.

Authors:  A H Conney
Journal:  Pharmacol Rev       Date:  1967-09       Impact factor: 25.468

4.  Metabolism of drugs. LIX. A new metabolite of antipyrine.

Authors:  H Yoshimura; H Shimeno; H Tsukamoto
Journal:  Biochem Pharmacol       Date:  1968-08       Impact factor: 5.858

5.  Metabolism of drugs. LXX. Further study on antipyrine metabolism.

Authors:  H Yoshimura; H Shimeno; H Tsukamoto
Journal:  Chem Pharm Bull (Tokyo)       Date:  1971-01       Impact factor: 1.645

6.  Norphenazone, a new metabolite of phenazone in human urine.

Authors:  J D Baty; D A Evans
Journal:  J Pharm Pharmacol       Date:  1973-01       Impact factor: 3.765

7.  Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man.

Authors:  E S Vesell; J G Page
Journal:  J Clin Invest       Date:  1969-12       Impact factor: 14.808

8.  Increased glucuronidation of bilirubin in man and rat by administration of antipyrine (phenazone).

Authors:  M L Orme; L Davies; A Breckenridge
Journal:  Clin Sci Mol Med       Date:  1974-04

9.  Anomalous results of studies on drug interaction in man. II. Halofenate (mk-185) and antipyrine, bishydroxycoumarin, and warfarin.

Authors:  E S Vesell; G T Passananti
Journal:  Pharmacology       Date:  1975       Impact factor: 2.547

10.  Drug interactions with warfarin: studies with dichloralphenazone, chloral hydrate and phenazone (antipyrine).

Authors:  A Breckenridge; M L Orme; S Thorgeirsson; D S Davies; R V Brooks
Journal:  Clin Sci       Date:  1971-04       Impact factor: 6.124

View more
  31 in total

1.  The influence of Org 10172, a low molecular weight heparinoid, on antipyrine metabolism and the effect of enzyme induction on the response to Org 10172.

Authors:  A De Boer; J C Stiekema; M Danhof; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

2.  Metabolism of the aldose reductase inhibitor ALO1567 in man.

Authors:  Y H Park; J E Hudson; R C Barker; B M York; R K Brazzell
Journal:  Br J Clin Pharmacol       Date:  1991-08       Impact factor: 4.335

Review 3.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

4.  Biliary excretion of antipyrine and its metabolites after cholecystectomy.

Authors:  H Mönig; J Wilhelmy; S John; E E Ohnhaus
Journal:  Br J Clin Pharmacol       Date:  1988-02       Impact factor: 4.335

5.  Antipyrine metabolite formation and excretion in patients with chronic renal failure.

Authors:  M W Teunissen; D Kampf; I Roots; N P Vermeulen; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

6.  The disposition of antipyrine and its metabolites in young and elderly healthy volunteers.

Authors:  J Posner; M Danhof; M W Teunissen; D D Breimer; P D Whiteman
Journal:  Br J Clin Pharmacol       Date:  1987-07       Impact factor: 4.335

Review 7.  Sex-related differences in drug disposition in man.

Authors:  K Wilson
Journal:  Clin Pharmacokinet       Date:  1984 May-Jun       Impact factor: 6.447

8.  A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients.

Authors:  E Perucca; A Hedges; K A Makki; M Ruprah; J F Wilson; A Richens
Journal:  Br J Clin Pharmacol       Date:  1984-09       Impact factor: 4.335

9.  Effects of salbutamol on the absorption and disposition of sulphamethoxazole in adult volunteers.

Authors:  G I Adebayo; T O Ogundipe
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1989 Jan-Mar       Impact factor: 2.441

Review 10.  Clinical pharmacokinetic considerations in the treatment of increased intracranial pressure.

Authors:  G Heinemeyer
Journal:  Clin Pharmacokinet       Date:  1987-07       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.